Abiomed, Inc.ABMDNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank93
3Y CAGR+12.1%
5Y CAGR+0.4%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+12.1%/yr
vs +9.0%/yr prior
5Y CAGR
+0.4%/yr
Recent acceleration
Acceleration
+3.1pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
1x
Modest growth
Streak
2 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2022 | 34.07% |
| 2021 | 23.41% |
| 2020 | 5.62% |
| 2019 | 24.18% |
| 2018 | 13.42% |
| 2017 | 33.42% |
| 2016 | 38.32% |
| 2015 | 17.15% |
| 2014 | 19.73% |
| 2013 | -5.57% |